54 publications

– Prebet T, Boissel N, Reutenauer S, Thomas X, Delaunay J, Cahn JY, Pigneux A, Quesnel B, Witz F, Thepot S, Ugo V, Terre C, Recher C, Tavernier E, Hunault M, Esterni B, Castaigne S, Guilhot F, Dombret H, Vey N.

Acute Myeloid Leukemia With Translocation (8;21) or Inversion (16) in Elderly Patients Treated With Conventional Chemotherapy: A Collaborative Study of the French CBF-AML Intergroup

. J Clin Oncol 2009. ;27(28):4747-53.

– Shimoni A, Leiba M, Schleuning M, Martineau G, Renaud M, Koren-Michowitz M, Ribakovski E, le Coutre P, Arnold R, Guilhot F, Nagler A.

Prior treatment with the tyrosine kinase inhibitors dasatinib and nilotinib allows stem cell transplantation (SCT) in a less advanced disease phase and does not increase SCT Toxicity in patients with chronic myelogenous leukemia and philadelphia positive acute lymphoblastic leukemia.

Leukemia 2009; 23(1):190-194.

– Mustjoki S, Ekblom M, Arstila TP, Dybedal I, Epling-Burnette PK, Guilhot F, Hjorth-Hansen H, Hoglund M, Kovanen P, Laurinolli T, Liesveld J, Paquette R, Pinilla-Ibarz J, Rauhala A, Shah N, Simonsson B, Sinisalo M, Steegmann JL, Stenke L, Porkka K.

Clonal expansion of T/NK-cells during tyrosine kinase inhibitor dasatinib therapy.

Leukemia 2009 ;23(8):1398-405.

– Bouatia-Naji N, Bonnefond A, Cavalcanti-Proenca C, Sparso T, Holmkvist J, Marchand M, Delplanque J, Lobbens S, Rocheleau G, Durand E, De Graeve F, Chevre JC, Borch-Johnsen K, Hartikainen AL, Ruokonen A, Tichet J, Marre M, Weill J, Heude B, Tauber M, Lemaire K, Schuit F, Elliott P, Jorgensen T, Charpentier G, Hadjadj S, Cauchi S, Vaxillaire M, Sladek R, Visvikis-Siest S, Balkau B, Levy-Marchal C, Pattou F, Meyre D, Blakemore AI, Jarvelin MR, Walley AJ, Hansen T, Dina C, Pedersen O, Froguel P.

A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk.

Nat Genet 2009; 41(1):89-94.

– Hochhaus A, O’Brien SG, Guilhot F, Druker BJ, Branford S, Foroni L, Goldman JM, Muller MC, Radich JP, Rudoltz M, Mone M, Gathmann I, Hughes TP, Larson RA.

Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.

Leukemia 2009; 23(6):1054-1061.

– Millot F, Cividin M, Brizard F, Chomel JC, Mechinaud F, Guilhot F.

Successful second allogeneic stem cell transplantation in second remission induced by dasatinib in a child with Philadelphia chromosome positive acute lymphoblastic leukemia.

Pediatr Blood Cancer 2009;52(7):891-2.

– Khoury HJ, Guilhot F, Hughes TP, Kim DW, Cortes JE.

Dasatinib treatment for Philadelphia chromosome-positive leukemias: practical considerations.

Cancer 2009;115(7):1381-94

– Nedelec C, Ragot S, Irani J, Pires C, Gil R, Dore B.

Effects by androgen suppression with luteinizing hormone on cognitive functions in men treated for cancer of prostate

. Prog Urol 2009; 19(1):47-53.

Jaafari N, Bachollet MS, Paillot C, Amiel A, Rotge JY, Lafay N, Quentin S, Wassouf I, Camus V, Senon JL, El Hage W.

Obsessive compulsive disorder in a patient with twiddler’s syndrome.

Pacing Clin Electrophysiol 2009; 32(3):399-402.

– Rotge JY, Dilharreguy B, Aouizerate B, Martin-Guehl C, Guehl D, Jaafari N, Langbour N, Bioulac B, Tignol J, Allard M, Burbaud P.

Inverse relationship between thalamic and orbitofrontal volumes in obsessive-compulsive disorder.

Prog Neuropsychopharmacol Biol Psychiatry. 2009 Jun 15;33(4):682-7.

– Mok E, Letellier G, Cuisset JM, Denjean A, Gottrand F, Alberti C, Hankard R.

Lack of functional benefit with glutamine versus placebo in Duchenne muscular dystrophy: a randomized crossover trial.

PLoS One 2009; 4(5):e5448.

– Morel M, Couturier J, Lafay-Chebassier C, Paccalin M, Page G.

PKR, the double stranded RNA-dependent protein kinase as a critical target in Alzheimer’s disease.

J Cell Mol Med. 2009 Aug;13(8A):1476-88.

– Markova IS, Jaafari N, Berrios GE.

Insight and obsessive-compulsive disorder: a conceptual analysis.

Psychopathology. 2009;42(5):277-82.

– Bouche G, Lepage B, Migeot V, Ingrand P.

Application of detecting and taking overdispersion into account in Poisson regression model.

Rev Epidemiol Sante Publique 2009. ;57(4):285-96.

– Choquet H, Cavalcanti-Proenca C, Lecoeur C, Dina C, Cauchi S, Vaxillaire M, Hadjadj S, Horber F, Potoczna N, Charpentier G, Ruiz J, Hercberg S, Maimaitiming S, Roussel R, Boenhnke M, Jackson AU, Patsch W, Krempler F, Voight BF, Altshuler D, Groop L, Thorleifsson G, Steinthorsdottir V, Stefansson K, Balkau B, Froguel P, Meyre D.

The T-381C SNP in BNP gene may be modestly associated with type 2 diabetes: an updated meta-analysis in 49 279 subjects.

Hum Mol Genet 2009; 18(13):2495-2501.

Hankard R.

Maternal obesity and breastfeeding

. Arch Pediatr 2009; 16(6):565-567.

Hankard R.

Specificity of pediatric clinical research

. Arch Pediatr. 2009 Jun;16(6):655-7.

– Damjanac M, Page G, Ragot S, Laborie G, Gil R, Hugon J, Paccalin M.

PKR, a cognitive decline biomarker, can regulate translation via two consecutive molecular targets p53 and Redd1 in lymphocytes of AD patients.

J Cell Mol Med 2009;13(8B):1823-32.

– Cortes JE, Egorin MJ, Guilhot F, Molimard M, Mahon FX.

Pharmacokinetic/pharmacodynamic correlation and blood-level testing in imatinib therapy for chronic myeloid leukemia.

Leukemia 2009;23(9):1537-44.

– Staub F, Tournoux-Facon C, Roumy J, Chaigneau C, Morichaut-Beauchant M, Levillain P, Prevost C, Aube C, Lebigot J, Oberti F, Galtier JB, Laumonier H, Trillaud H, Bernard PH, Blanc JF, Sironneau S, Machet F, Drouillard J, de L, V, Couzigou P, Foucher P, Castera L, Tranquard F, Bacq Y, d’Alteroche L, Ingrand P, Tasu JP.

Liver fibrosis staging with contrast-enhanced ultrasonography: prospective multicenter study compared with METAVIR scoring.

Eur Radiol 2009; 19(8):1991-1997.

– Hu Y, Kaisaki PJ, Argoud K, Wilder SP, Wallace KJ, Woon PY, Blancher C, Tarnow L, Groop PH, Hadjadj S, Marre M, Parving HH, Farrall M, Cox RD, Lathrop M, Vionnet N, Bihoreau MT, Gauguier D.

Functional annotations of diabetes nephropathy susceptibility loci through analysis of genome-wide renal gene expression in rat models of diabetes mellitus.

BMC Med Genomics 2009; 2(1):41.

Ingrand I, Dujoncquoy S, Beauchant M, Letard JC, Migeot V, Ingrand P.

General practitioner and specialist views on colonoscopic screening of first-degree relatives of colorectal cancer patients.

Cancer Epidemiol 2009 ;33(3-4):223-30.

– Riveline JP, Teynie J, Belmouaz S, Franc S, Dardari D, Bauwens M, Caudwell V, Ragot S, Bridoux F, Charpentier G, Marechaud R, Hadjadj S.

Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system.

Nephrol Dial Transplant 2009 ;24(9):2866-71.

Guilhot F, Druker B, Larson RA, Gathmann I, So C, Waltzman R, O’Brien SG.

High rates of durable response are achieved with imatinib after treatment with interferon alpha plus cytarabine: results from the International Randomized Study of Interferon and STI571 (IRIS) trial.

Haematologica 2009;94(12):1669-75

– Baccarani M, Cortes J, Pane F, Niederwieser D, Saglio G, Apperley J, Cervantes F, Deininger M, Gratwohl A, Guilhot F, Hochhaus A, Horowitz M, Hughes T, Kantarjian H, Larson R, Radich J, Simonsson B, Silver RT, Goldman J, Hehlmann R.

Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet.

J Clin Oncol 2009;27(35):6041-51.

– Chomel JC, Sorel N, Bonnet ML, Bertrand A, Brizard F, Saulnier PJ, Roy L, Guilhot F, Turhan AG.

Quantitative monitoring of the T315I mutation in patients with chronic myeloid leukemia (CML).

Leuk Res 2009; 33(4):551-555.

– Rung J, Cauchi S, Albrechtsen A, Shen L, Rocheleau G, Cavalcanti-Proenca C, Bacot F, Balkau B, Belisle A, Borch-Johnsen K, Charpentier G, Dina C, Durand E, Elliott P, Hadjadj S, Jarvelin MR, Laitinen J, Lauritzen T, Marre M, Mazur A, Meyre D, Montpetit A, Pisinger C, Posner B, Poulsen P, Pouta A, Prentki M, Ribel-Madsen R, Ruokonen A, Sandbaek A, Serre D, Tichet J, Vaxillaire M, Wojtaszewski JF, Vaag A, Hansen T, Polychronakos C, Pedersen O, Froguel P, Sladek R.

Genetic variant near IRS1 is associated with type 2 diabetes, insulin resistance and hyperinsulinemia.

Nat Genet 2009. ;41(10):1110-5.

– Enea C, Boisseau N, Ottavy M, Mulliez J, Millet C, Ingrand I, Diaz V, Dugue B.

Effects of menstrual cycle, oral contraception, and training on exercise-induced changes in circulating DHEA-sulphate and testosterone in young women.

Eur J Appl Physiol 2009; 106(3):365-373.

– Godeneche G, Sorel N, Ragot S, Chomel JC, Neau JP, Macchi L.

Stroke and aspirin non-responder patients: Relation with hypertension and platelet response to adenosine diphosphate.

Platelets 2009;20(7):471-7.

– Karayan-Tapon L, Quillien V, Guilhot J, Wager M, Fromont G, Saikali S, Etcheverry A, Hamlat A, Loussouarn D, Campion L, Campone M, Vallette FM, Gratas-Rabbia-Re C.

Prognostic value of O(6)-methylguanine-DNA methyltransferase status in glioblastoma patients, assessed by five different methods.
J Neurooncol 2009;97(3):311-22.

– Lavault S, Bloch F, Houeto JL, Konofal E, Welter ML, Agid Y, Arnulf I.

Periodic leg movements and REM sleep without atonia in Parkinson’s disease with camptocormia.

Mov Disord 2009 ;24(16):2419-23.

– Rotge JY, Langbour N, Guehl D, Bioulac B, Jaafari N, Allard M, Aouizerate B, Burbaud P.

Gray Matter alterations in Obsessive-Compulsive Disorder: an anatomic likelihood estimation meta-analysis.

Neuropsychopharmacology. 2010 Feb;35(3):686-91.

Saulnier PJ, Piguel X, Perault-Pochat MC, Csizmadia-Bremaud C, Saulnier JP.

Hypoglycaemic seizure and neonatal acute adrenal insufficiency after maternal exposure to prednisone during pregnancy: a case report.

Eur J Pediatr 2009. 2010 Jun;169(6):763-5.

Guilhot F, Roy L, Saulnier PJ, Guilhot J.

Interferon in chronic myeloid leukaemia: past and future.

Best Pract Res Clin Haematol 2009; 22(3):315-329.

– Cortes JE, Baccarani M, Guilhot F, Druker BJ, Branford S, Kim DW, Pane F, Pasquini R, Goldberg SL, Kalaycio M, Moiraghi B, Rowe JM, Tothova E, De Souza C, Rudoltz M, Yu R, Krahnke T, Kantarjian HM, Radich JP, Hughes TP.

Phase III, Randomized, Open-Label Study of Daily Imatinimb Mesylate 400 mg Versus 800 mg in Patients With Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase Using Molecular End Points: Tyrosine Kinase Inhibitor Optimization and Selectivity Study.

J Clin Oncol 2009;28(3):424-30.

– Kong A, Steinthorsdottir V, Masson G, Thorleifsson G, Sulem P, Besenbacher S, Jonasdottir A, Sigurdsson A, Kristinsson KT, Jonasdottir A, Frigge ML, Gylfason A, Olason PI, Gudjonsson SA, Sverrisson S, Stacey SN, Sigurgeirsson B, Benediktsdottir KR, Sigurdsson H, Jonsson T, Benediktsson R, Olafsson JH, Johannsson OT, Hreidarsson AB, Sigurdsson G, the DIAGRAM Consortium, Ferguson-Smith AC, Gudbjartsson DF, Thorsteinsdottir U, Stefansson K.

Parental origin of sequence variants associated with complex diseases.

Nature. 2009 Dec 17;462(7275):868-74.

– Rotge JY, Langbour N, Jaafari N, Guehl D, Bioulac B, Aouizerate B, Allard M, Burbaud P.

Anatomical Alterations and Symptom-Related Functional Activity in Obsessive-Compulsive Disorder Are Correlated in the Lateral Orbitofrontal Cortex.

Biol Psychiatry. 2010 Apr 1;67(7):e37-8.

– Seite F, Delelis-Fanien AS, Valero S, Pradère C, Poupet JY, Ingrand P, Paccalin M.

Compliance with guidelines for proton pump inhibitor prescriptions in a department of geriatrics.

J Am Geriatr Soc. 2009;57(11):2169-70.

– Hagenbeek A, Fayad L, Delwail V, Rossi JF, Jacobsen E, Kuliczkowski K, Link BK, Pinter-Brown L, Radford J, Hellmann A, Gallop-Evans E, Gupta I, Arning M, Begtrup K, Schultz M, Bang B, Russell CA, Czuczman MS.

Evaluation of Ofatumumab, a Novel Human CD20 Monoclonal Antibody, as Single Agent Therapy in Rituximab-Refractory Follicular Lymphoma.

Blood 2009; 114(22):935.

– Fauveau A, Lacotte-Thierry L, Fleck E, Colin JY, Guilhot F, Chabin M, Langlois A, Guilhot J, Delwail V.

Phase I/II Study of Escalating Doses of Idarubicin Orally Given with Oral Cyclophosphamide, Etoposide, Prednisolone and Intravenous Rituximab in Elderly Patients with Disseminated High Grade Non Hodgkin Lymphoma.

Blood 2009; 114(22):3695.

– Marcelli D, Delamour M, Ingrand I, Ingrand P.

Répétition d’accident à l’adolescence : étude prospective de l’échelle d’évaluation des circonstances de l’accident et du risque de récidive (ECARR).

Neuropsychiatrie de l’enfance et de l’adolescence 57(2009)344–367.

– Apperley JF, Cortes JE, Kim DW, Roy L, Roboz GJ, Rosti G, Bullorsky EO, Abruzzese E, Hochhaus A, Heim D, de Souza CA, Larson RA, Lipton JH, Khoury HJ, Kim HJ, Sillaber C, Hughes TP, Erben P, Van Tornout J, Stone RM.

Dasatinib in the treatment of chronic myeloid leukemia in accelerated phase after imatinib failure: the START a trial.

J Clin Oncol. 2009;27(21):3472-9.

– Baccarani M, Druker BJ, Cortes-Franco J, Hughes TP, Kim DW, Pane F, Branford S, Jin Y, Krahnke T, Rudoltz M, Radich JP, Guilhot F.

24 Months Update of the TOPS Study: a Phase III, Randomized, Open-Label Study of 400mg/d (SD-IM) Versus 800mg/d (HD-IM) of Imatinib Mesylate (IM) in Patients (Pts) with Newly Diagnosed, Previously Untreated Chronic Myeloid Leukemia in Chronic Phase (CML-CP).

Blood 2009; 114(22):337.

– Emmanuel Nicolini F, Etienne G, Bordessoule D, Caillot D, Belanger C, Cayuela JM, Charbonnier A, Coiteux V, Guerci-Bresler A, Dubruille V, Lamy T, Huguet F, Rousselot P, Tulliez M, Cahn JY, Gardembas-Pain M, Legros L, Maloisel F, Rea D, Johnson-Ansah H, Lenain P, Delmer A, Berger M, Szczudlo T, Wang J, Duh MS, Guilhot F.

Molecular Response, Efficacy and Safety Analysis of 168 Adult French Patients with Chronic Myeloid Leukemia (CML) in Chronic Phase (CP) From the ENACT (Expanding Nilotinib Access in Clinical Trials) Study.

Blood (ASH Annual Meeting Abstracts), 2009; 114: 3293.

– Deininger M, O’Brien SG, Guilhot F, Goldman JM, Hochhaus A, Hughes TP, Radich JP, Hatfield AK, Mone M, Filian J, Reynolds J, Gathmann I, Larson RA, Druker BJ.

International Randomized Study of Interferon Vs STI571 (IRIS) 8-Year Follow up: Sustained Survival and Low Risk for Progression or Events in Patients with Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Treated with Imatinib.

Blood 112:abstr 186.

– Kim DW, Granvil C, Demirhan E, Reynolds J, Jin Y, Wang Y, Baccarani M, Cortes-Franco J, Druker BJ, Hughes TP, Guilhot F

Comparison of Steady-State Imatinib (IM) Trough Levels, Clinical Response, and Safety Between Caucasian and Asian Patients with Chronic Lyeloid Leukemia in Chronic Phase (CML-CP) Treated with 400mg and 800mg Daily Doses of IM in the Tyrosine Kinase Inhibitor Optimization and Selectivity (TOPS) Study.

Blood 2009; 114(22):1127.

– Mahon FX, Rea D, Guilhot F, Huguet F, Nicolini FE, Legros L, Charbonnier A, Guerci A, Varet BR, Etienne G, Aton E, Reiffers J, Rousselot P.

Discontinuation of Imatinib Therapy After Achieving a Molecular Response in Chronic Myeloid Leukemia Patients.

Blood 2009; 114(22):859.

– Olivier G, Gardembas M, Delwail V, Le Mevel A, Escoffre-Barbe M, Brion A, Boulet JM, Solal-Celigny P, Ingrand P, Colombat P.

Phase I/II Study of Escalating Doses of Idarubicin in Combination with Methotrexate, Vindesine and Prednisolone in Patients with Primary Central Nervous System Lymphoma: Results of the GOELAMS LCP99 Multicenter Trial.

Blood 2009; 114(22):2694.

– Bonnefond A, Vaxillaire M, Labrune Y, Lecoeur C, Chèvre JC, Bouatia-Naji N, Cauchi S, Balkau B, Marre M, Tichet J, Riveline JP, Hadjadj S, Gallois Y, Czernichow S, Hercberg S, Kaakinen M, Wiesner S, Charpentier G, Lévy-Marchal C, Elliott P, Jarvelin MR, Horber F, Dina C, Pedersen O, Sladek R, Meyre D, Froguel P.

Genetic variant in HK1 is associated with a proanemic state and A1C but not other glycemic control-related traits.

Diabetes. 2009;58(11):2687-97.

– Assessing glycemic control in maintenance hemodialysis patients with type 2 diabetes: response to Kazempour-Ardebili et al. Riveline JP, Hadjadj S.

Diabetes Care. 2009 Dec;32(12):e155

– Ianotto JC, Kiladjian JJ, Demory JL, Roy L, Boyer F, Rey J, Dupriez B, Berthou C, Abgrall JF.

PEG-IFN-alpha-2a therapy in patients with myelofibrosis: a study of the French Groupe d’Etudes des Myelofibroses (GEM) and France Intergroupe des syndromes Myéloprolifératifs (FIM).

Br J Haematol. 2009 Jul;146(2):223-5.

– Lefort B, Giraud C, Saulnier JP, Bott L, Gambert C, Sosner P, Hankard R.

Treatment of homozygous familial hypercholesterolemia with LDL-apheresis on a 4-year-old child.

Arch Pediatr ; 16(12):.1554-1558.

– Laurent G, de Micheaux SL, Solal-Celigny P, Soubeyran P, Delwail V, Ghesquieres H, Thieblemont C, Jourdan E, Beautier L, Audibert F, Squiban P, Sicard H, Rossi JF.

Phase I/II Study of IPH1101, gamma sigma T Cell Agonist, Combined with Rituximab, in Low Grade Follicular Lymphoma Patients.

Blood 2009; 114(22):1649.

– Neau JP, Ingrand P, Godeneche G.

Awareness within the French population concerning stroke signs, symptoms, and risk factors.

Clin Neurol Neurosurg. 2009 ;111(8):659-64.


Menu principal

Haut de page